Adamis Pharmaceuticals reported 10.92M in Operating Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Adma Biologics ADMA:US $ 50.59M 11.01M
Brainstorm Cell Therapeutics BCLI:US $ 5.48M 737K
Cara Therapeutics CARA:US $ 32.7M 1.64M
Cerulean Pharma CERU:US $ 8.4M 1.14M
GlaxoSmithKline GSK:LN 5.85B 1.13B
Glaxosmithkline GSK:US 5.85B 1.13B
Merk MRK:US $ 9666M 666M
Pfizer PFE:US $ 15640M 148M
Redhill Biopharma RDHL:US 31.47M 11.3M